

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	40/444,909 10/807,508	
			Filing Date	April 3, 2002	
			First Named Inventor	Stanley M Crain	
			Art Unit	1614	
			Examiner Name	Raymond J. Henley III	
Sheet	1	of	1	Attorney Docket Number	96700/748

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
[Signature]	1	US- 5,580,876	12-03-1996	Crain et al.	
	2	US- 5,585,348	12-17-1996	Crain et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
[Signature]	3	EP 0 352 361 A1	01-31-1990	The Rockefeller University		

Examiner Signature	[Signature]	Date Considered	2/27/05
-----------------------	-------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known	
Application Number	09/281,381 10/807,508			
Filing Date	March 3, 1999			
First Named Inventor	Stanley M. Crain			
Group Art Unit	1614			
Examiner Name	Ray Henley			
Attorney Docket Number	96700/453			

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T‡
[Signature]	1	CHAMI, et al., Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C) with the Opioid Antagonist Nalmefene Glucuronide (NG), The American Journal of Gastroenterology 1993, 88(9), 1568.		
	2	FARTHING, New Drugs in the Management of the Irritable Bowel Syndrome, Drugs 1998:56(1), 11-21.		
	3	DAPOIGNY, et al., Efficacy of Peripheral Kappa Agonist Fedotozine versus Placebo in Treatment of Irritable Bowel Syndrome, Digestive Diseases and Sciences 1995, 40(10) 2244-2248.		
	4	DROSSMAN, et al., Irritable Bowel Syndrome: A Technical Review for Practice Guideline Development, Gastroenterology 1997, 112:2120-2137.		
	5	DALTON, et al., Diagnosis and Treatment of Irritable Bowel Syndrome, American Family Physician 1997, 55(3):875-880.		
	6	CAMILLERI, et al., Review Article: Irritable Bowel Syndrome, Aliment. Pharmacol. Ther. 1997, 11:3-15.		
	7	PACE, et al., Therapy of Irritable Bowel Syndrome - An Overview, Digestion 1995, 56:433-442.		
	8	DELVAUX, et al., Trimebutine: Mechanism of Action, Effects on Gastrointestinal Function and Clinical Results, The Journal of International Medical Research 1997, 25:225-246.		
	9	DAPOIGNY, et al., Neurophysiology and Neuropsychiatry of the IBS, Digestion 1997, 58:1-9.		
	10	JUNIEN, et al., Review Article: The Hypersensitive Gut - Peripheral Kappa Agonists as a New Pharmacological Approach, Aliment. Pharmacol. Ther. 1995, 9:117-126.		
[Signature]	11	GUE, et al., The K Agonist Fedotozine Modulates Colonic Distention - Induced Inhibition of Gastric Motility and Emptying in Dogs, Gastroenterology 1994, 107:1327-1334.		

Examiner Signature [Signature]	Date Considered 2/27/05
---------------------------------------------------------------------------	--------------------------------------------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Unique citation designation number. ‡ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
Sheet	2	of	3	Application Number	00/264,361 10/807,508
				Filing Date	March 3, 1999
				First Named Inventor	Stanley M. Crain
				Group Art Unit	1614
				Examiner Name	Ray Henley
				Attorney Docket Number	96700/453

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
A	12	DROSSMAN, et al., Psychosocial Factors in the Irritable Bowel Syndrome, Gastroenterology 1988, 95:701-8.	
	13	DROSSMAN, et al., U.S. Householder Survey of Functional Gastrointestinal Disorders, Digestive Diseases and Sciences, 1993, 38(9):1569-1580.	
	14	TALLEY, et al., Medical Costs in Community Subjects with Irritable Bowel Syndrome, Gastroenterology 1995, 109:1736-1741.	
	15	KONIECZKO, et al., Antagonism of Morphine-Induced Respiratory Depression with Nalmefene, Br. J. Anaesth. 1988, 61:318-323.	
	16	WANG, et al., Morphine Tolerance and Physical Dependence: Reversal of Opioid Inhibition to Enhancement of Cyclic AMP Formation, Journal of Neurochemistry 1995, 64(3):1102-1106.	
	17	JOSHI, et al., Effects of prophylactic Nalmefene on the Incidence of Morphine-related Side Effects in Patients Receiving Intravenous Patient-controlled Analgesia, Anesthesiology 1999, 90:1007-11.	
	18	XU, et al., Opioids Can Enhance and Inhibit the Electrically Evoked Release of Methionine-Enkephalin, Brain Research 1989, 504:36-42.	
	19	GINTZLER, Relevance of Opioid Bimodality to Tolerance/Dependence Formation, Advances in Experimental Medicine and Biology, 373:73-83. (NO DATE AVAILABLE)	
	20	HORAN, et al., Antinociceptive Profile of Biphallin, a Dimeric enkephalin Analog, The J. of Phar. and Exper. Ther. 265(3):1446-1454. (NO DATE AVAILABLE)	
	21	CHESKIN, et al., Assessment of Nalmefene Glucuronide as a Selective Gut Opioid Antagonist, Drug and Alcohol Dependence 1995, 39:151-154.	
B	22	GAN, et al., Opioid-sparing Effects of a Low-dose Infusion of Naloxone in Patient-administered Morphine Sulfate, Anesthesiology 1997, 87:1075-81.	

Examiner Signature		Date Considered	2/27/05
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/088 (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	09/261,361 10/807,508	
			Filing Date	March 3, 1999	
			First Named Inventor	Stanley M. Crain	
			Group Art Unit	1614	
			Examiner Name	Ray Henley	
Sheet	3	of	3	Attorney Docket Number	96700/453

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	23	CRAIN, et al., Modulation of Opioid Analgesia, Tolerance and Dependence by Gs-coupled, GM1 Ganglioside-regulated Opioid receptor Functions, TIPS 1998, 19:358-365.	
	24	CRAIN, et al., GM1 Ganglioside-induced Modulation of Opioid Receptor-mediated Functions, Annals of the New York Academy of Sciences 1998:106-125.	
	25	APFEL, et al., Kappa Opioid Receptors Participate in Nerve Growth Factor-Induced Hyperalgesia, Neuroscience 1995, 68(4):1199-1206.	
	26	SHEN, et al., Nerve Growth Factor Rapidly Prolongs the Action Potential of Mature Sensory Ganglion Neurons in Culture, and This Effect Requires Activation of Gs-coupled Excitatory k-Opioid Receptors on These Cells, The Journal of Neuroscience 1994, 14(9):5570-5579.	
	27	SHEN, et al., Ultra-low Doses of Naltrexone or Etorphine Increase Morphine's Antinociceptive Potency and attenuate Tolerance/Dependence in Mice, Brain Research 1997, 757:176-190.	
	28	SHEN, et al., Biphallin, an Enkephalin Analgo with Unexpectedly High Antinociceptive Potency and Low Dependence Liability in Vivo, Selectively antagonized Excitatory Opioid Receptor Functions of Sensory Neurons in Culture, Brain Research 1995, 701:158-166.	
	29	SHEN, et al., Chronic Selective Activation of Excitatory Opioid Receptor Functions in Sensory Neurons Results in Opioid 'Dependence' Without Tolerance, Neuroscience 1992, 597:74-83.	
	30	CRAIN, After Chronic Opioid Exposure Sensory Neurons Become Supersensitive to the Excitatory Effects of Opioid Agonists and Antagonists as Occurs After Acute Elevation of GM1 Ganglioside, Brain Research 1992, 575:13-24.	
	31	CRAIN, et al., Opioids can Evoke Direct Receptor-Mediated Excitatory Effects on Sensory Neurons, Pharmacological Sciences 1990, 11(2):77-81.	
	32	CRAIN, et al., Ultra-low Concentrations of Naloxone Selectively Antagonize Excitatory Effects of Morphine on Sensory Neurons, Thereby Increasing its Antinociceptive Potency and Attenuating Tolerance/Dependence During Chronic Cotreatment, Proc. Natl. Acad. Sci. (USA) 1995, 92:10540-10544.	
	33	SHEN, et al., Dual Opioid Modulation of the Action Potential Duration of Mouse Dorsal Root Ganglion Neurons in Culture, Brain Research 1989, 491:227-242.	

Examiner Signature		Date Considered	2/27/05
--------------------	--	-----------------	---------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.